Span Divergent approves Aranya revival after ₹14.95 crore losses

Span Divergent Limited approved a plan to revive Aranya Consulting and Biotech LLP after the formerly non-operational subsidiary accumulated losses of ₹14.95 crore by March 31, 2026 and recorded a further ₹1.37 lakh loss through September 30, 2026. The Board also reclassified the LLP’s assets as property, plant and equipment, or PPE, citing potential new opportunities.

What did Span Divergent approve for Aranya Consulting?

Span Divergent approved a plan to revive Aranya Consulting from its non-operational state, as disclosed in the notes to its results for the half year ended September 30, 2026. The Board reviewed and approved those results on November 5, 2026, and said the decision reflected the potential of new opportunities emerging for the LLP.

Aranya Consulting is the short form for Aranya Consulting and Biotech LLP, which was formerly named Aranya Agri Biotech LLP and changed its name effective May 19, 2026. The filing does not identify a product, customer, business tie-up, capital budget, start date, revenue forecast or profitability target for the revival plan.

The disclosed action is therefore a Board-approved operating plan, rather than confirmation that Aranya Consulting had resumed commercial operations by September 30, 2026. The filing links the decision to new opportunities but does not quantify their expected financial effect or explain how they could address the accumulated losses reported at March 31, 2026.

How much has Aranya Consulting lost?

Aranya Consulting had accumulated losses of ₹14.95 crore as at March 31, 2026 and incurred a further loss of ₹1.37 lakh in the period up to September 30, 2026. The ₹14.95 crore figure is a cumulative balance, while the ₹1.37 lakh amount relates to the first half of the financial year, so the two amounts are not like-for-like periods.

The filing shows that losses continued to be recorded after the LLP’s May 19, 2026 name change and before the results were approved on November 5, 2026. It does not disclose Aranya Consulting’s revenue, expenses, assets, liabilities or cash flow for the six months ended September 30, 2026.

Span Divergent’s standalone results provide the wider reporting context but are not Aranya Consulting’s results. The parent reported a loss after tax of ₹31.29 lakh for the six months ended September 30, 2026, compared with a profit after tax of ₹53.69 lakh for the six months ended September 30, 2025.

Why did Span Divergent reclassify Aranya Consulting’s assets as PPE?

Span Divergent said Aranya Consulting’s assets were reclassified as PPE in connection with the Board-approved plan to revive the LLP. PPE is the filing’s stated classification for the assets, but the note does not disclose their value, type, location, depreciation impact or individual accounting entries.

The company tied the classification change to moving Aranya Consulting away from its non-operational state as at the September 30, 2026 reporting period. It did not describe the reclassification as an asset sale, acquisition or disposal, and it gave no date for when the LLP may commence operations.

At the parent-company level, standalone PPE stood at ₹2.8745 crore on September 30, 2026, down from ₹2.9524 crore on March 31, 2026. That movement cannot be used to value Aranya Consulting’s reclassified assets because the balance sheet is labelled standalone and the subsidiary note provides no amount.

How do Aranya Consulting’s losses compare with other subsidiaries?

Aranya Consulting’s disclosed accumulated losses of ₹14.95 crore were higher than those reported for the other two subsidiaries discussed in the September 30, 2026 notes. Biospan Contamination Control Solution Private Limited reported accumulated losses of ₹7.69 crore through September 30, 2026, while Biospan Scientific LLP reported ₹1.57 crore as at March 31, 2019.

The reported dates differ, so the figures compare disclosed cumulative-loss balances rather than one common accounting period. Biospan Scientific’s investment was impaired by ₹1.83 crore after accumulated losses caused substantial erosion of its net worth as at March 31, 2019, although management said it was exploring revival independently or through business tie-ups.

Biospan Contamination Control Solution had total liabilities exceeding total assets by ₹7.59 crore on September 30, 2026. Management said that subsidiary’s results were prepared on a going-concern basis because it believed the losses were temporary and that product introductions could generate adequate revenue, but Span Divergent made no corresponding product-introduction statement for Aranya Consulting.

What is the financial context for the revival plan?

Span Divergent recorded net cash outflow from investing activities of ₹5.7607 crore in the half year ended September 30, 2026, compared with ₹20.53 lakh in the year ended March 31, 2026. Purchases or redemptions of investments in subsidiaries accounted for ₹6.1136 crore during the half year, but the filing does not name the subsidiary or subsidiaries involved.

Cash and cash equivalents were ₹1.74 lakh at September 30, 2026, compared with ₹5.8523 crore at March 31, 2026. The cash-flow statement reported an operating cash outflow of ₹53.26 lakh and an investing cash outflow of ₹5.7607 crore for the half year, partly offset by a financing cash inflow of ₹45.84 lakh.

Span Divergent raised ₹5.7936 crore through a preferential issue allotted on March 28, 2026 and said the proceeds allocated to stated objects were fully utilised by the quarter ended September 30, 2026, with no deviation. The disclosed allocations were ₹5 crore for raw cashew nut inventory, ₹50 lakh for restart and ramp-up costs, and ₹29.36 lakh for selective refurbishment; the filing does not connect these uses specifically to Aranya Consulting.

Conclusion

Span Divergent has approved a plan to revive Aranya Consulting despite accumulated losses of ₹14.95 crore at March 31, 2026 and a further ₹1.37 lakh loss through September 30, 2026. The reclassification of the LLP’s assets as PPE is linked to intended operating use, but the filing does not state the asset value, timing of the restart, or expected revenue and profit contribution.

The next disclosed milestone to watch is evidence that the revival plan is being executed, including any update on operating activity, subsidiary investment, revenue or losses after November 5, 2026. Investors can also monitor whether future filings identify the recipient of the ₹6.1136 crore subsidiary-investment movement reported in the half-year cash-flow statement.